MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
9 Meters Biopharma Gross Profit 2011-2026 | NMTR
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit 9 Meters Biopharma
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -64 K | 736 K | 426 K | 234 K | 606 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 736 K | -64 K | 388 K |
Quarterly Gross Profit 9 Meters Biopharma
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -70 K | -39 K | -47 K | - | 92 K | 430 K | 47 K | - | 532 K | 86 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 532 K | -70 K | 129 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-1.72 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
9.02 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
225 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
42.7 M | $ 34.42 | 4.65 % | $ 926 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
9.54 M | $ 6.84 | 2.17 % | $ 187 M |  Israel |
 |
Grifols, S.A.
GRFS
|
2.79 B | $ 8.21 | 4.72 % | $ 5.58 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
114 M | $ 0.85 | 0.57 % | $ 142 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
63.5 M | $ 2.74 | 0.18 % | $ 256 M | Israel |
 |
Anika Therapeutics
ANIK
|
63.8 M | $ 15.15 | 2.23 % | $ 217 M | USA |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M | Canada |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 3.39 | 4.17 % | $ 5.58 M | Israel |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
339 M | $ 1.52 | 2.7 % | $ 178 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |